X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Cadila: Racing ahead - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jul 9, 2002

    Cadila: Racing ahead

    A 16% rise in turnover reported by Cadila for FY02 is quite encouraging, especially considering the fact that the first half yearly growth was a mere 7%. On an annual basis, operating margins have also shown an improvement. The company has ambitious plans to emerge amongst the top 3 pharmaceutical companies in India by March 2004. Post the acquisition of controlling stake in German Remedies, the company is open to further in-organic growth.

    (Rs m) FY01 FY02 Change
    Sales 5,088 5,888 15.7%
    Other Income 74 41 -44.1%
    Expenditure 4,351 4,997 14.8%
    Operating Profit (EBDIT) 737 891 20.9%
    Operating Profit Margin (%) 14.5% 15.1%
    Interest (46) 11 -123.8%
    Depreciation 149 188 26.1%
    Profit before Tax 708 734 3.6%
    Tax 55 62 12.5%
    Profit after Tax/(Loss) 653 672 2.9%
    Net profit margin (%) 12.8% 11.4%  
    No. of Shares (eoy) (m) 60 60  
    Diluted Earnings per share* 10.9 11.2  
    P/E (at current price) 12.1  

    The strong growth rate in the last two quarters has been possible due to launch of new products in the neuroscience division, acquisition of perpetual rights to market five leading brands from Asta and acquisition of 'Aten' brand from Kopran last year. Further, the company has also logged several co-marketing alliances with Kopran, Ranbaxy and E-Merck. However, margins in this business are low compared to other businesses which partially explains the drop in overall margins.Realising its over dependence on few slow growing therapeutic segments, the company has made some rapid moves, including acquisitions, which will strongly position the company in some of the fast growing therapeutic segments. In its bid to further fuel in-organic growth, Cadila acquired the Vadodara-based Banyan Chemicals Ltd (BCL) for Rs 205 m.

    The acquisition of BCL is expected to help the company in exploring export markets. BCL already has a US FDA approved unit for the manufacture of bulk drugs with export sales of Rs 250 m to Geneva Pharmaceuticals Technology Corporation of the US, a subsidiary of Novartis. The company plans to rapidly penetrate the export markets in the US through BCL. While the acquisition of BCL would give Cadila direct entry into the US bulk drug market, exports of formulations would take another two years, as the company is in the process of getting US FDA approval for the formulation plant. Cadila has plans to keep BCL as a separate subsidiary, though it may consider merging it with itself later.

    It may be recalled that the company acquired a 27.7% stake in German Remedies for a consideration of Rs 1.5 bn last year. It also acquired perpetual rights to market five leading brands from Asta (one of the promoter of German Remedies). Post that the company did an open offer for the shareholders of German Remedies, taking the total stake in the company to 55.4%. The financing of the same would be done through a mix of debt (Rs 2,000 m) and internal accruals. The company has made a secondary open offer for German Remedies shareholders at a price of Rs 300/- per share for acquiring the remaining shareholding (45%) in GRL. In the event of the company's shareholding crossing 90% through the proposed open offer, it plans to seek the delisting of GRL.

    Cadila-German Remedies: Merged Picture
    Rs m Cadila German Remedies Merged Entity*
    Net Sales 5,888 1,960 7,848
    Operating Margins (%) 15.1% 19.1% 16.1%
    Net Profit 672 249 921
    EPS (Rs.) NA NA 15.4

    The in-organic growth strategy of Cadila group has no doubt helped it to create a robust entity. However, what is concerning is the rising interest burden on the company. The debt figure has risen considerably in last one year to fund its acqusitions and research initiatives. The payback period of these acquisitions would have to justify the rise in interest costs. Further, the company has yet to prove its performance in the exports market. The valuations of the company going forward would thus depend on how fast the debt backed acquisitions of the company payoff. At the current market price of Rs 135, the stock trades at 9x its FY02 earnings on a consolidated basis.

     

     

    Equitymaster requests your view! Post a comment on "Cadila: Racing ahead". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

    Aug 21, 2017

    Most Indians who cannot find jobs, look at becoming self-employed.

    It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

    Aug 16, 2017

    The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

    Aug 22, 2017

    Post demonetisation, a cut in bank savings deposits rates was in the offing.

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    CADILA HEALTHCARE SHARE PRICE


    Aug 24, 2017 10:59 AM

    TRACK CADILA HEALTHCARE

    • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    MORE ON CADILA HEALTHCARE

    CADILA HEALTHCARE 8-QTR ANALYSIS

    Detailed Quarterly Results With Charts

    COMPARE CADILA HEALTHCARE WITH

    MARKET STATS